Indictment of Osteopathic Physician Signals Shift in Peptide Enforcement

There has been a recent and sudden uptick in enforcement from federal agencies against medspa prescribers. Specifically, the Department of Justice (DOJ) recently indicted a licensed osteopathic physician for allegedly receiving and selling misbranded drugs to patients and received a guilty plea from a medspa owner for importing merchandise contrary to law, as well as selling or dispensing a counterfeit drug and selling or dispensing a counterfeit device.

These efforts are consistent with the FDA’s first ever warning letter to a clinic regarding the use of unapproved drug sources for aesthetic treatments. They represent the culmination of the continuing cat and mouse game that state regulators have been playing with practitioners where new and proposed laws around medspas are created, but not adequately enforced.

This crackdown is the culmination of a trend that began around 2020, when GLP-1 shortages, exacerbated by the COVID-19 pandemic, created a vacuum in the pharmaceutical market. Federal enforcement marks a tidal shift in regulatory enforcement.

The Rise of the “Compounding Loophole”

To address these shortages, the FDA permitted 503B compounding pharmacies to produce GLP-1 medications, initially for diabetes, and eventually for weight loss. However, as the market grew into a multibillion-dollar industry, some entities began leveraging this status to mass-market unapproved substances.

Shift from Shortages to “Patient-Specific” Batching

As official drug shortages were resolved, 503B pharmacies pivoted. After unsuccessfully suing the FDA to maintain shortage status, many shifted toward 503A compounding, which requires medications to be patient-specific.

To circumvent manufacturing restrictions, these pharmacies often created large batches of drugs and added minor ingredients, such as a single vitamin, to claim that the formula was a “unique” patient-specific compound. This practice, intended to suggest that the drug would not interfere with safety or efficacy, has not always held up under clinical or regulatory scrutiny.

Prescriber Behavior Changes

Many providers viewed this as a legitimate “end-run” to provide treatments, asserting that they were simply engaged in the practice of medicine or responding to patient needs. Compounded products lack proven safety, efficacy and therefore do not necessarily adhere to the established standard of care. This surge in unverified treatments eventually triggered House and Senate interest.

Regulatory Red Flags

State boards of pharmacy, medicine and nursing, along with various Attorneys General, have identified several critical concerns regarding these “medspa” services, as outlined below:

• Absentee Supervision: Physicians who are not meaningfully involved in patient care, relying instead on nurses to provide treatments outside their scope of practice
• Salt Versions: The use of salt-based versions of products like semaglutide, often falsely marketed as approved or labeled as “research chemicals”
• Regulatory End-Runs: Clinicians claiming products are for “research” while simultaneously marketing them as generic versions of Mounjaro or Ozempic
• Lack of Safety Infrastructure: A failure to maintain emergency preparedness for injectables, such as lacking onsite oxygen or epinephrine for anaphylaxis

Federal Enforcement

Once the shortages for Mounjaro and Ozempic officially resolved, some providers moved into more aggressive territory: unapproved peptides. On April 1, 2026, a Utah-licensed osteopathic physician, Dr. Watkins, was indicted for allegedly receiving and selling misbranded, non-FDA-approved peptides to over 200 patients. The indictment covers a wide array of substances, including: Tirzepatide, Semaglutide, Retatrutide, Cagrilintide, BPC-157, TB500, Ipamorelin, CJC-1295, GHK, GHK-Cu, NAD+. These products were sold despite being on the informally named “503A do not compound list,” which includes bulk drug substances considered for the 503A Bulks list but ultimately excluded, meaning they cannot be used to compound products that qualify for section 503A exemptions.

This trend toward high-risk sourcing has triggered a nationwide crackdown. On the same day as the Watkins indictment, the FDA issued a warning letter to Pure Indulgence Aesthetics for violating the Drug Supply Chain Security Act by sourcing prescription drugs from unauthorized trading partners. This follows a high-profile case in Massachusetts where medspa owner Rebecca Fadanelli pled guilty on April 7, 2026, to performing thousands of injections using counterfeit Botox and fillers imported from China and Brazil.

In response to these escalating risks, legislative bodies are tightening oversight; for instance, the Florida Senate recently introduced the “Medical Spa Prescription Drug Oversight Act” (SB 1728) to mandate strict licensing and public databases for facilities handling such medications. Across these cases, products were often sold at deep discounts despite an apparent lack of reliable testing or clinical trials, posing significant safety risks to patients.

A New Era of Prosecution

This case aligns with the administration’s heightened commitment to prosecuting providers and pharmacists who enable the distribution of unapproved products. It serves as a stark warning to the medical community: the era of “regulatory flexibility” regarding compounded peptides has come to an end.